AIMS/HYPOTHESIS: Recent findings suggest the potential involvement of adiponectin in obesity, diabetes and cardiovascular disease. We assessed the prospective association between adiponectin concentration and coronary artery disease in individuals with type 1 diabetes. METHODS: Participants were identified from the Pittsburgh Epidemiology of Diabetes Complications cohort, a prospective follow-up study of childhood-onset type 1 diabetes. At baseline, subjects had a mean age of 28 years, and a mean diabetes duration of 19 years. Cases (determined by physician-diagnosed angina, confirmed myocardial infraction, stenosis >or=50%, ischemic ECG or revascularization) were matched to the control subjects with respect to sex, age and diabetes duration. Samples and risk factors for analyses were identified from the earliest exam prior to incidence in cases. Sera and information on all covariates were available for 28 cases and 34 control subjects. Proportional hazards models were constructed including matching variables. RESULTS: Compared with those in men, adiponectin concentrations were elevated in females (p=0.009) and among individuals with macroalbuminuria (p=0.04). In multivariable analyses (adjusting for standard risk factors as well as lipoprotein measurements determined by nuclear magnetic resonance spectroscopy, E-selectin or antioxidants), adiponectin inversely predicted the incidence of coronary artery disease (hazard ratio=0.37 per 1 SD increase, 95% CI 0.19-0.73, p=0.004). CONCLUSIONS/ INTERPRETATION: The results suggest that increased adiponectin concentration is prospectively associated with a lower risk of coronary artery disease type 1 diabetes. The potential of adiponectin determination as a useful marker of, and potential therapeutic target for, coronary artery disease prevention in type 1 diabetes should be further explored.
AIMS/HYPOTHESIS: Recent findings suggest the potential involvement of adiponectin in obesity, diabetes and cardiovascular disease. We assessed the prospective association between adiponectin concentration and coronary artery disease in individuals with type 1 diabetes. METHODS:Participants were identified from the Pittsburgh Epidemiology of Diabetes Complications cohort, a prospective follow-up study of childhood-onset type 1 diabetes. At baseline, subjects had a mean age of 28 years, and a mean diabetes duration of 19 years. Cases (determined by physician-diagnosed angina, confirmed myocardial infraction, stenosis >or=50%, ischemic ECG or revascularization) were matched to the control subjects with respect to sex, age and diabetes duration. Samples and risk factors for analyses were identified from the earliest exam prior to incidence in cases. Sera and information on all covariates were available for 28 cases and 34 control subjects. Proportional hazards models were constructed including matching variables. RESULTS: Compared with those in men, adiponectin concentrations were elevated in females (p=0.009) and among individuals with macroalbuminuria (p=0.04). In multivariable analyses (adjusting for standard risk factors as well as lipoprotein measurements determined by nuclear magnetic resonance spectroscopy, E-selectin or antioxidants), adiponectin inversely predicted the incidence of coronary artery disease (hazard ratio=0.37 per 1 SD increase, 95% CI 0.19-0.73, p=0.004). CONCLUSIONS/ INTERPRETATION: The results suggest that increased adiponectin concentration is prospectively associated with a lower risk of coronary artery disease type 1 diabetes. The potential of adiponectin determination as a useful marker of, and potential therapeutic target for, coronary artery disease prevention in type 1 diabetes should be further explored.
Authors: Y Okamoto; Y Arita; M Nishida; M Muraguchi; N Ouchi; M Takahashi; T Igura; Y Inui; S Kihara; T Nakamura; S Yamashita; J Miyagawa; T Funahashi; Y Matsuzawa Journal: Horm Metab Res Date: 2000-02 Impact factor: 2.936
Authors: Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa Journal: Biochem Biophys Res Commun Date: 1999-04-02 Impact factor: 3.575
Authors: Joachim Spranger; Anja Kroke; Matthias Möhlig; Manuela M Bergmann; Michael Ristow; Heiner Boeing; Andreas F H Pfeiffer Journal: Lancet Date: 2003-01-18 Impact factor: 79.321
Authors: Linda Broer; Julia Raschenberger; Joris Deelen; Massimo Mangino; Veryan Codd; Kirsi H Pietiläinen; Eva Albrecht; Najaf Amin; Marian Beekman; Anton J M de Craen; Christian Gieger; Margot Haun; Peter Henneman; Christian Herder; Iiris Hovatta; Annika Laser; Lyudmyla Kedenko; Wolfgang Koenig; Barbara Kollerits; Eeva Moilanen; Ben A Oostra; Bernhard Paulweber; Lydia Quaye; Aila Rissanen; Michael Roden; Ida Surakka; Ana M Valdes; Katriina Vuolteenaho; Barbara Thorand; Ko Willems van Dijk; Jaakko Kaprio; Tim D Spector; P Eline Slagboom; Nilesh J Samani; Florian Kronenberg; Cornelia M van Duijn; Karl-Heinz Ladwig Journal: Eur J Epidemiol Date: 2014-07-27 Impact factor: 8.082
Authors: Lewis H Kuller; Gregory Grandits; Jerome D Cohen; James D Neaton; Ronald Prineas Journal: Atherosclerosis Date: 2006-10-02 Impact factor: 5.162
Authors: Maria Dalamaga; Ilias Migdalis; Jessica L Fargnoli; Evangelia Papadavid; Erica Bloom; Nicholas Mitsiades; Konstantinos Karmaniolas; Nicolaos Pelecanos; Sofia Tseleni-Balafouta; Amalia Dionyssiou-Asteriou; Christos S Mantzoros Journal: Cancer Causes Control Date: 2008-12-03 Impact factor: 2.506
Authors: Amy S Shah; Lawrence M Dolan; Abigail Lauer; Cralen Davis; Dana Dabelea; Stephen R Daniels; Richard F Hamman; Santica Marcovina; R Paul Wadwa; Elaine M Urbina Journal: J Pediatr Endocrinol Metab Date: 2012 Impact factor: 1.634
Authors: Kevin Jon Williams; Gang Qiu; Hitomi Katoaka Usui; Stephen R Dunn; Peter McCue; Erwin Bottinger; Renato V Iozzo; Kumar Sharma Journal: Am J Pathol Date: 2007-09-20 Impact factor: 4.307